Dose-Dependent Effect of Landiolol, a New Ultra-Short-Acting β(1)-Blocker, on Supraventricular Tachyarrhythmias in Postoperative Patients

Antzeko izenburuak

• The Effectiveness and Safety of Landiolol Hydrochloride, an Ultra-Short-Acting β(1)-Blocker, in Postoperative Patients with Supraventricular Tachyarrhythmias: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
  nork: Taenaka, Nobuyuki, et al.
  Argitaratua: (2013)
• Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis
  nork: Okajima, Masaki, et al.
  Argitaratua: (2015)
• Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction
  nork: Wada, Yuko, et al.
  Argitaratua: (2016)
• Efficacy of Intravenous Administration of Landiolol in Patients With Acute Heart Failure and Supraventricular Tachyarrhythmia
  nork: Kiuchi, Shunsuke, et al.
  Argitaratua: (2017)
• Characteristic interactivity of landiolol, an ultra-short-acting highly selective β(1)-blocker, with biomimetic membranes: Comparisons with β(1)-selective esmolol and non-selective propranolol and alprenolol
  nork: Tsuchiya, Hironori, et al.
  Argitaratua: (2013)